7 In patients who meet these criteria, the ADA preferably recommends use of a GLP-1 RA with proven cardiovascular benefit or an SGLT-2 inhibitor with proven cardiovascular benefit provided they have adequate kidney function
CagriSema is a combination of semaglutide and the amylin analog cagrilintide
the prototype MT-II itself has remained without an active clinical development sponsor since 2000
Consistent patient reports, however, may indicate a potential link worth further investigation
Our findings suggest that compared to insulin therapy, the higher drug acquisition, pharmacy, and outpatient costs associated with the real-world use of a GLP-1RA is offset by a reduction in healthcare-related expenses associated with emergency room visits and inpatient admissions owing to reduced risks of all-cause mortality and hospitalized hypoglycemia
Insulin remains the preferred choice only when GLP-1 drugs are contraindicated, unaffordable, or insufficient alone, or when the patient has Type 1 diabetes